Chemours (CC) Reports Q2 Earnings: What Key Metrics Have to Say

Chemours (CC) reported robust Q2 2025 earnings, with revenue of $1.62 billion, up 5% year-over-year and beating consensus by 2.98%, and EPS of $0.58, significantly exceeding the $0.46 estimate by 26.09%. While key segments like Advanced Performance Materials and Thermal & Specialized Solutions showed strong Adjusted EBITDA, Titanium Technologies' EBITDA missed estimates. Despite the headline beats, CC shares have underperformed the S&P 500 over the last month, declining 1.7%, and the stock holds a Zacks Rank #5 (Strong Sell), suggesting potential near-term underperformance.

Analysis

Chemours (CC) delivered a robust second-quarter performance, with revenue of $1.62 billion and EPS of $0.58, representing year-over-year growth of 5% and 52.6% respectively. Both top and bottom-line figures surpassed Wall Street consensus estimates, with a notable +26.09% EPS surprise. The positive results were largely driven by the Thermal & Specialized Solutions segment, which posted a 16.4% year-over-year revenue increase and exceeded its Adjusted EBITDA forecast. However, a critical look at the segment data reveals underlying weakness in the company's largest division, Titanium Technologies. This segment experienced a 2.4% year-over-year revenue decline and its Adjusted EBITDA of $47 million fell short of the $50 million analyst estimate. This miss in a core segment, coupled with the stock's 1.7% decline over the past month against a rising S&P 500, suggests investor apprehension. The negative sentiment is explicitly captured by the stock's Zacks Rank #5 (Strong Sell), indicating a bearish near-term outlook despite the strong headline earnings.

Key Decisions for Investors

• Investors should look past the strong headline earnings and revenue beat to scrutinize the conflicting performance across business segments.
• The primary risk factor is the Titanium Technologies division, where a 2.4% year-over-year revenue decline and a miss on Adjusted EBITDA estimates signal potential margin pressure in the company's largest unit.
• Given the stock's recent underperformance relative to the market and the explicit 'Strong Sell' rating from Zacks, a cautious or bearish stance may be warranted, as the positive earnings surprise may not be enough to overcome near-term headwinds.